Hinova Pharmaceuticals (SH:688302) Ge Long Hui A P P·2026-01-30 13:31Core Viewpoint - The company expects to reduce its losses significantly in 2025, with projected total profits ranging from -150 million to -125 million yuan, indicating a year-on-year loss reduction of 24.81% to 37.34% [1] Financial Projections - The company anticipates a net profit attributable to shareholders of the parent company for 2025 to be between -150 million and -125 million yuan, reflecting a decrease in losses by 49.49 million to 74.49 million yuan compared to the previous year [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -185 million and -155 million yuan, which represents a reduction in losses by 32.51 million to 62.51 million yuan year-on-year, equating to a decrease of 14.95% to 28.74% [1] Product Development - The company’s first Class 1 new drug, Deutetrabenazine soft capsules (Project No: HC-1119), is expected to be approved for market sale in May 2025, which will contribute to revenue growth despite the current limited sales from materials and intermediates [1]